Travere Therapeutics, Inc.
General ticker "TVTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.6B (TTM average)
Travere Therapeutics, Inc. follows the US Stock Market performance with the rate: 59.3%.
Estimated limits based on current volatility of 1.5%: low 65.51$, high 67.29$
Factors to consider:
- Total employees count: 385 as of 2024
- Top business risk factors: FDA approval delays, Commercialization challenges, Sales force deficit, Adverse safety events, Market competition
- Current price 43.8% above estimated high
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [20.73$, 46.74$]
- 2026-12-31 to 2027-12-31 estimated range: [15.18$, 35.94$]
Financial Metrics affecting the TVTX estimates:
- Negative: with PPE of -126.9 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 0.82 > -0.64
- Positive: Interest expense per share per price, % of 0.32 <= 0.75
- Positive: 18.97 < Shareholder equity ratio, % of 18.97 <= 42.26
- Positive: Inventory ratio change, % of -0.25 <= 0
- Positive: 0.28 < Operating cash flow per share per price, % of 1.11
Short-term TVTX quotes
Long-term TVTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $145.24MM | $233.18MM | $490.73MM |
| Operating Expenses | $533.38MM | $557.00MM | $553.55MM |
| Operating Income | $-388.14MM | $-323.83MM | $-62.82MM |
| Non-Operating Income | $12.03MM | $3.32MM | $13.55MM |
| Interest Expense | $11.33MM | $11.18MM | $10.75MM |
| R&D Expense | $244.99MM | $282.70MM | $206.01MM |
| Income(Loss) | $-376.11MM | $-320.51MM | $-49.27MM |
| Taxes | $0.22MM | $0.12MM | $0.99MM |
| Other Income(Loss) | $264.93MM | $-0.92MM | $24.71MM |
| Net Income(Loss)* | $-111.40MM | $-321.55MM | $-25.55MM |
| Stockholders Equity | $200.81MM | $59.08MM | $114.83MM |
| Inventory | $9.41MM | $6.20MM | $5.88MM |
| Assets | $788.91MM | $594.12MM | $605.19MM |
| Operating Cash Flow | $-280.02MM | $-237.47MM | $37.78MM |
| Capital expenditure | $41.59MM | $101.21MM | $58.16MM |
| Investing Cash Flow | $55.78MM | $99.33MM | $27.89MM |
| Financing Cash Flow | $218.75MM | $139.42MM | $-33.47MM |
| Earnings Per Share** | $-1.50 | $-4.08 | $-0.29 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.